Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 January 2007, Vol. 109, No. 1, pp. 112-121.
Prepublished online as a Blood First Edition Paper on September 19, 2006; DOI 10.1182/blood-2006-05-020784.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Table
Right arrow Erratum (v111,p3299)
Right arrow All Versions of this Article:
blood-2006-05-020784v1
109/1/112    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodeve, A.
Right arrow Articles by Peake, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodeve, A.
Right arrow Articles by Peake, I.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted May 5, 2006
Accepted August 22, 2006

Phenotype and genotype of a cohort of families historically diagnosed with Type 1 von Willebrand Disease in the European study, molecular and clinical markers for the diagnosis and management of Type 1 von Willebrand Disease (MCMDM-1VWD)

Anne Goodeve*, Jeroen Eikenboom, Giancarlo Castaman, Francesco Rodeghiero, Augusto B. Federici, Javier Batlle, Dominique Meyer, Claudine Mazurier, Jenny Goudemand, Reinhard Schneppenheim, Ulrich Budde, Jorgen Ingerslev, David Habart, Zdena Vorlova, Lars Holmberg, Stefan Lethagen, John Pasi, Frank Hill, Mohammad Hashemi Soteh, Luciano Baronciani, Christer Hallden, Andrea Guilliatt, Will Lester, and Ian Peake

Academic Unit of Haematology, University of Sheffield, Sheffield, UK
Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
Hematology Department, San Bortolo Hospital, Vicenza, Italy
Hematology Department of San Bortolo Hospital, Vicenza, Italy
Hemophilia and Thrombosis Centre, University of Milan, Milan, Italy
Servicio de Hamatologia y Hemoterapia, Hospital Teresa Herrera, La Coruna, Spain
INSERM U143, INSERM, Paris, France
Laboratoire Francais du Fractionnement et des Biotechnologies, Lille, France
University of Lille, Lille, France
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Coagulation Laboratory, Hamburg, Germany
Centre for Haemophilia and Thrombosis, University Hospital Skejby, Aarhus, Denmark
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
Department of Paediatrics, University of Lund, Lund, Sweden
Department for Coagulation Disorders, University of Lund, Malmo, Sweden
Department of Pathology, Leicester Royal Infirmary, Leicester, UK
Department of Haematology, Children's Hospital, Birmingham, UK
Academic Unit of Haemotology, University of Sheffield, Sheffield, UK

* Corresponding author; email: a.goodeve{at}shef.ac.uk.

Type 1 von Willebrand disease (VWD) is characterized by a personal and family history of bleeding, co-incident with reduced levels of normal plasma von Willebrand factor (VWF). The molecular basis of the disorder is poorly understood. The aims of this study were to determine phenotype and genotype and their relationship in patients historically diagnosed with type 1 VWD. Families were recruited in nine European countries based on previous type 1 VWD diagnosis. Bleeding symptoms were recorded, plasma phenotype analyzed, and VWF mutation analysis performed in all index cases (IC). Phenotypic and molecular analysis stratified patients into those with/without phenotypes suggestive of qualitative VWF defects (abnormal multimers) and with/without mutations. 105 of 150 IC (70%) had mutations identified. A subgroup with abnormal multimers (38% IC, 57/150) showed a high prevalence of VWF gene mutations (95% of IC, 54/57), whereas in those with qualitatively normal VWF, fewer mutations were identified (55% of IC, 51/93). About one third of the type 1 VWD cases recruited could be reconsidered as type 2. The remaining group could be considered "true" type 1 VWD, although mutations were found in only 55%.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

VWD data worth 10 000 words
J. Evan Sadler
Blood 2007 109: 3. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
F. Rodeghiero, G. Castaman, and A. Tosetto
How I treat von Willebrand disease
Blood, August 6, 2009; 114(6): 1158 - 1165.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. C. Goodeve
When 1 plus 1 equals 3 in VWD
Blood, July 30, 2009; 114(5): 933 - 934.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. S. Sutherland, A. M. Cumming, M. Bowman, P. H. B. Bolton-Maggs, D. J. Bowen, P. W. Collins, C. R. M. Hay, A. M. Will, and S. Keeney
A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3
Blood, July 30, 2009; 114(5): 1091 - 1098.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. B Federici and M. T. Canciani
Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease
Haematologica, May 1, 2009; 94(5): 610 - 615.
[Full Text] [PDF]


Home page
haematolHome page
A. Perez-Rodriguez, A. Garcia-Rivero, E. Loures, M. F. Lopez-Fernandez, A. Rodriguez-Trillo, and J. Batlle
Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications
Haematologica, May 1, 2009; 94(5): 679 - 686.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. E. Daly, B. B. Dawood, W. A. Lester, I. R. Peake, F. Rodeghiero, A. C. Goodeve, M. Makris, J. T. Wilde, A. D. Mumford, S. P. Watson, et al.
Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study
Blood, April 23, 2009; 113(17): 4110 - 4113.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. L. Haberichter, G. Castaman, U. Budde, I. Peake, A. Goodeve, F. Rodeghiero, A. B. Federici, J. Batlle, D. Meyer, C. Mazurier, et al.
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)
Blood, May 15, 2008; 111(10): 4979 - 4985.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Tosetto, G. Castaman, and F. Rodeghiero
Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach
Blood, April 15, 2008; 111(8): 3998 - 4003.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Castaman, S. Lethagen, A. B. Federici, A. Tosetto, A. Goodeve, U. Budde, J. Batlle, D. Meyer, C. Mazurier, E. Fressinaud, et al.
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
Blood, April 1, 2008; 111(7): 3531 - 3539.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. H. Soteh, I. R Peake, L. Marsden, J. Anson, J. Batlle, D. Meyer, E. Fressinaud, C. Mazurier, J. Goudemand, J. Eikenboom, et al.
Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques
Haematologica, April 1, 2007; 92(4): 550 - 553.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Davies, P. W. Collins, L. S. Hathaway, and D. J. Bowen
Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group
Blood, April 1, 2007; 109(7): 2840 - 2846.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. J. M. van Schooten, C. V. Denis, T. Lisman, J. C. J. Eikenboom, F. W. Leebeek, J. Goudemand, E. Fressinaud, H. M. van den Berg, P. G. de Groot, and P. J. Lenting
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels
Blood, March 15, 2007; 109(6): 2430 - 2437.
[Abstract] [Full Text] [PDF]


Home page
JWatch Oncology and HematologyHome page
What Is Type 1 von Willebrand Disease?
Journal Watch Oncology and Hematology, January 22, 2007; 2007(122): 5 - 5.
[Full Text]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020